Retatrutide Side Effects: What Clinical Trials Show

No drug delivers 71 pounds of weight loss without side effects. Understanding retatrutide's side effect profile — and how it compares to tirzepatide and semaglutide — is essential for anyone considering it once approved.

Here's what clinical trial data actually shows.

Most Common Side Effects

From Phase 2 and available Phase 3 data, the most frequently reported side effects are:

• Nausea — most common, especially during dose escalation (weeks 1-12)
• Vomiting — less common than nausea, peaks early
• Diarrhea
• Constipation
• Decreased appetite — expected and desired for weight loss
• Fatigue — particularly early in treatment
• Injection site reactions — mild redness or bruising at injection site

These side effects are similar to other TRT medications. In clinical trials, the majority of participants who completed the escalation phase reported that GI effects significantly improved or resolved. Discontinuation due to side effects occurred in a small minority of participants.

The Glucagon Effect: Heart Rate

This is where retatrutide differs from semaglutide and tirzepatide. Glucagon receptor activation increases metabolic rate — which is part of why retatrutide produces greater weight loss. But glucagon also tends to increase heart rate.

Phase 2 data showed modest increases in resting heart rate in retatrutide-treated patients — typically 4-8 beats per minute above baseline at higher doses. This is considered mild in healthy adults but represents a meaningful consideration for:

• Patients with pre-existing heart rhythm disorders
• Patients taking medications that affect heart rate
• Patients with structural heart disease

Phase 3 cardiovascular outcomes data will clarify the long-term significance of this effect. Until that data is available, anyone with cardiovascular concerns should discuss them with their provider before considering retatrutide.

GI Side Effects: What to Expect

The nausea timeline for retatrutide follows the pattern of other TRT drugs, but may be more pronounced during escalation:

• Weeks 1-4: Nausea peaks. This is the dose escalation phase — your body is adjusting to each new dose level. Small, frequent meals, eating slowly, and avoiding high-fat foods significantly reduce symptoms.
• Weeks 4-12: GI effects gradually improve as your body adapts to each dose level.
• Week 12+: Most patients report significant reduction in GI side effects. Those who push through the escalation phase typically tolerate the maintenance dose well.

Practical tips from tirzepatide/semaglutide patients that will likely apply to retatrutide:

• Eat smaller portions more frequently
• Avoid fried, fatty, or heavily spiced foods during escalation
• Stay well hydrated
• Don't eat within 2 hours of your injection
• Take the injection in the evening if morning nausea is severe

How Retatrutide Compares to Tirzepatide

Who Should Be Cautious

• People with cardiovascular disease — wait for cardiovascular outcomes data
• People with heart rhythm disorders — the heart rate effect needs evaluation
• People with a personal or family history of medullary thyroid carcinoma — same caution as all TRT drugs
• Pregnant or breastfeeding women — not studied; avoid
• People with severe GI disorders — GI effects may be difficult to manage

For most healthy adults with obesity, retatrutide's side effect profile appears manageable based on trial data. The key is proper dose escalation and close monitoring — which is why medical oversight matters. Don't use unregulated compounded versions; the dose escalation protocol is essential for tolerability.